Best Medulloblastoma Treatment Doctors in India
Whatsapp Us
Dr. Pramod Kumar Julka
Dr. Ramandeep Singh Arora
Dr. Raman Deep Singh Arora
What Parents of a Child with Medulloblastoma Worry About Most
Medulloblastoma is the most common malignant brain tumour in children. Parents arrive scared and overwhelmed: how soon does surgery need to happen, will the child have lasting weakness or balance problems, what does craniospinal radiation do to growth and learning, will the child be able to go back to school, and what are the long-term effects on hormones and fertility. Modern molecular subgrouping (WNT, SHH, Group 3, Group 4) now guides risk stratification and intensity of treatment.
How Medulloblastoma Is Diagnosed
Most children present with morning headaches, vomiting, and unsteadiness due to a posterior fossa mass blocking cerebrospinal fluid flow. Magnetic resonance imaging of the brain and spine confirms the tumour and looks for spinal seeding. After surgery, histology and molecular subgrouping define the variant. Lumbar puncture checks for tumour cells in cerebrospinal fluid. Staging as standard-risk or high-risk depends on age, residual tumour, dissemination, and molecular subgroup.
Treatment Options for Medulloblastoma in India
Maximal safe surgical resection in the posterior fossa is the first step, with hydrocephalus often managed at the same time by endoscopic third ventriculostomy or shunt. Standard-risk children over three years receive craniospinal radiation with a boost to the tumour bed, followed by chemotherapy with cisplatin, vincristine, lomustine, and cyclophosphamide. High-risk disease gets higher radiation doses and more intensive chemotherapy. Very young children avoid radiation when possible, using high-dose chemotherapy with autologous stem cell rescue to delay or omit radiation. WNT-subgroup patients with excellent prognosis may eventually receive reduced therapy on clinical trials. Fortis Memorial Research Institute, Medanta, BLK-Max, Apollo, Manipal, NIMHANS, and All India Institute of Medical Sciences run paediatric neuro-oncology programmes capable of full medulloblastoma protocols.
Recovery, Success Rates, and Follow-Up
Standard-risk medulloblastoma in children over three has a five-year survival of seventy-five to eighty-five percent. High-risk disease has fifty to seventy percent survival depending on subgroup. WNT-subgroup tumours have over ninety-five percent cure rates. Hospital stay after craniotomy is seven to ten days. Radiation runs for six weeks. Maintenance chemotherapy continues for nine to twelve months. Long-term follow-up includes endocrine surveillance, hearing tests, neurocognitive assessment, and magnetic resonance imaging surveillance for at least ten years.
How to Choose the Right Doctor
Look for a paediatric neurosurgeon with focused medulloblastoma practice, working with a paediatric hemato-oncologist and a radiation oncologist experienced in craniospinal irradiation. Ask whether molecular subgrouping is performed, whether the radiation oncology team uses intensity-modulated or proton therapy to reduce damage to growing tissues, whether the centre has paediatric intensive care, and whether long-term endocrine and neurocognitive follow-up is available.
Support for International Patients
The full medulloblastoma protocol in India, including molecular testing, craniospinal radiation, and maintenance chemotherapy, costs a fraction of equivalent care in the United Kingdom, United States, or Middle East. Cancer Rounds arranges the medical visa invitation letter, airport pickup, family accommodation near the treatment hospital for the extended stay, multilingual support in eleven plus languages, and full coordination with the paediatric neuro-oncology unit. Families from Nigeria, Bangladesh, Kenya, Ethiopia, Iraq, Oman, the United Arab Emirates, and other countries travel to India for medulloblastoma care.
Frequently Asked Questions
Is medulloblastoma curable?
Yes, for most children. Standard-risk medulloblastoma has a cure rate of seventy-five to eighty-five percent. WNT-subgroup tumours have over ninety-five percent cure rates. High-risk disease cure depends on molecular subgroup.
What is craniospinal radiation?
Craniospinal radiation treats the whole brain and spinal cord because medulloblastoma can seed along cerebrospinal fluid pathways. The tumour bed in the posterior fossa receives an additional boost. Modern intensity-modulated and proton techniques reduce long-term side effects.
Can radiation be avoided in young children?
In children under three years, high-dose chemotherapy with autologous stem cell rescue is used to delay or avoid craniospinal radiation, because radiation at this age causes serious long-term cognitive and growth effects.
What are the long-term effects of treatment?
Long-term effects can include hormone deficiencies, hearing loss, learning difficulties, and rarely second cancers. Modern proton therapy and intensity-modulated radiation therapy reduce these risks. Long-term follow-up by paediatric endocrinology, neurology, and audiology is part of survivorship care.
What is molecular subgrouping?
Medulloblastoma now has four molecular subgroups (WNT, SHH, Group 3, Group 4) with very different prognoses. Subgrouping guides treatment intensity and is performed in dedicated paediatric neuro-oncology centres in India.
When can my child go back to school?
Most children resume school during maintenance chemotherapy, around six to nine months after diagnosis. Learning support and physical therapy help with any residual difficulties. Long-term neurocognitive follow-up is part of standard care.
